In last trading session, ARS Pharmaceuticals Inc (NASDAQ:SPRY) saw 1.8 million shares changing hands with its beta currently measuring 0.87. Company’s recent per share price level of $18.08 trading at $0.82 or 4.75% at ring of the bell on the day assigns it a market valuation of $1.78B. That closing price of SPRY’s stock is at a discount of -2.38% from its 52-week high price of $18.51 and is indicating a premium of 57.63% from its 52-week low price of $7.66. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 1.48 million shares which gives us an average trading volume of 1.50 million if we extend that period to 3-months.
For ARS Pharmaceuticals Inc (SPRY), analysts’ consensus is at an average recommendation of Buy while assigning it a mean rating of 1.00. Splitting up the data highlights that, out of 4 analysts covering the stock, 0 rated the stock as a Sell while 0 recommended an Overweight rating for the stock. 0 suggested the stock as a Hold whereas 4 see the stock as a Buy. 0 analyst(s) advised it as an Underweight.
ARS Pharmaceuticals Inc (NASDAQ:SPRY) trade information
Upright in the green during last session for gaining 4.75%, in the last five days SPRY remained trading in the green while hitting it’s week-highest on Thursday, 06/26/25 when the stock touched $18.08 price level, adding 0.71% to its value on the day. ARS Pharmaceuticals Inc’s shares saw a change of 119.42% in year-to-date performance and have moved 13.64% in past 5-day. ARS Pharmaceuticals Inc (NASDAQ:SPRY) showed a performance of 23.67% in past 30-days. Number of shares sold short was 16.58 million shares which calculate 12.13 days to cover the short interests.
Wall Street analysts have assigned a consensus price target of 22 to the stock, which implies a rise of 17.82% to its current value. Analysts have been projecting 18 as a low price target for the stock while placing it at a high target of 30. It follows that stock’s current price would jump 0.44% in reaching the projected high whereas dropping to the targeted low would mean a gain of 0.44% for stock’s current value.
In 2025, company’s earnings growth rate is likely to be around -1939.17% while estimates for its earnings growth in next 5 years are of 60.25%.
ARS Pharmaceuticals Inc (NASDAQ:SPRY)’s Major holders
Insiders are in possession of 21.23% of company’s total shares while institution are holding 80.28 percent of that, with stock having share float percentage of 101.91%. Investors also watch the number of corporate investors in a company very closely, which is 80.28% institutions for ARS Pharmaceuticals Inc that are currently holding shares of the company. DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) is the top institutional holder at SPRY for having 11.08 million shares of worth $94.27 million. And as of 2024-06-30, it was holding 11.4409 of the company’s outstanding shares.
The second largest institutional holder is RA CAPITAL MANAGEMENT, L.P., which was holding about 10.86 million shares on 2024-06-30. The number of shares represents firm’s hold over 11.2168 of outstanding shares, having a total worth of $92.43 million.
